Literature DB >> 19749005

Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study.

Evans R Fernández Pérez1, Craig E Daniels, Darrell R Schroeder, Jennifer St Sauver, Thomas E Hartman, Brian J Bartholmai, Eunhee S Yi, Jay H Ryu.   

Abstract

BACKGROUND: Limited data exist regarding the population-based epidemiology of idiopathic pulmonary fibrosis (IPF). The objective of the study was to describe the trends in the incidence, prevalence, and clinical course of IPF in the community.
METHODS: We conducted a population-based study of adult patients with IPF in Olmsted County, Minnesota, from 1997 to 2005. Two methods were used to identify IPF cases, as defined by the 2002 American Thoracic Society/European Respiratory Society consensus statement: (1) usual interstitial pneumonia (UIP) on a surgical lung biopsy specimen or a definite UIP pattern on a high-resolution CT image (narrow criteria) and (2) UIP on a surgical lung biopsy specimen or a definite or possible UIP pattern on CT image (broad criteria).
RESULTS: Of 596 patients screened for the possibility of pulmonary disease or pulmonary fibrosis over 9 years of follow-up, 47 cases had IPF. Of these, 24 met the narrow criteria. The age- and sex-adjusted incidence was 8.8/100,000 and 17.4/100,000 person-years, for narrow and broad criteria, respectively. The age-adjusted incidence was higher in men than in women, and among patients aged 70-79 years. During the study period, the incidence of IPF decreased (P < .001). On December 31, 2005, the age- and sex-adjusted prevalence was 27.9/100,000 and 63/100,000 persons by narrow and broad criteria, respectively. Thirty-seven patients experienced a total of 53 respiratory exacerbations (26 IPF related, 27 non-IPF related), and 34 (72%) patients died. The primary cause of death was IPF related in 16 (47%) patients. Median survival for narrow-criteria and broad-criteria incidence cases was 3.5 and 4.4 years, respectively.
CONCLUSIONS: The incidence of IPF in Olmsted County decreased over the study period. Nonprimary IPF respiratory exacerbations are as frequent as primary IPF respiratory exacerbations and an important cause of death.

Entities:  

Mesh:

Year:  2009        PMID: 19749005      PMCID: PMC2803118          DOI: 10.1378/chest.09-1002

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  22 in total

1.  First report of the Italian register for diffuse infiltrative lung disorders (RIPID).

Authors:  C Agostini; C Albera; F Bariffi; M De Palma; S Harari; M Lusuardi; A Pesci; V Poletti; L Richeldi; G Rizzato; A Rossi; M Schiavina; G Semenzato; C Tinelli
Journal:  Monaldi Arch Chest Dis       Date:  2001-08

Review 2.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

3.  Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis.

Authors:  G W Hunninghake; M B Zimmerman; D A Schwartz; T E King; J Lynch; R Hegele; J Waldron; T Colby; N Müller; D Lynch; J Galvin; B Gross; J Hogg; G Toews; R Helmers; J A Cooper; R Baughman; C Strange; M Millard
Journal:  Am J Respir Crit Care Med       Date:  2001-07-15       Impact factor: 21.405

Review 4.  Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots.

Authors:  Steven D Nathan; Paul W Noble; Rubin M Tuder
Journal:  Am J Respir Crit Care Med       Date:  2007-01-25       Impact factor: 21.405

Review 5.  Interstitial lung diseases: an epidemiological overview.

Authors:  M Demedts; A U Wells; J M Antó; U Costabel; R Hubbard; P Cullinan; H Slabbynck; G Rizzato; V Poletti; E K Verbeken; M J Thomeer; J Kokkarinen; J C Dalphin; A N Taylor
Journal:  Eur Respir J Suppl       Date:  2001-09

6.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.

Authors:  T E King; J A Tooze; M I Schwarz; K R Brown; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-10-01       Impact factor: 21.405

7.  [How are interstitial lung diseases diagnosed in Germany? Results of the scientific registry for the exploration of interstitial lung diseases ("Fibrosis registry") of the WATL].

Authors:  H Schweisfurth; C Kieslich; N Satake; R Loddenkemper; N Schönfeld; I Mäder; D Treutler; W Matthiessen; C Schmidt; P Leonhardt; G Siemon; N deWall; U Gereke; U Costabel
Journal:  Pneumologie       Date:  2003-07

8.  Association between pulmonary fibrosis and coronary artery disease.

Authors:  Jorge R Kizer; David A Zisman; Nancy P Blumenthal; Robert M Kotloff; Stephen E Kimmel; Robert M Strieter; Selim M Arcasoy; Victor A Ferrari; John Hansen-Flaschen
Journal:  Arch Intern Med       Date:  2004-03-08

9.  Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community.

Authors:  C von Plessen; O Grinde; A Gulsvik
Journal:  Respir Med       Date:  2003-04       Impact factor: 3.415

10.  Report on the incidence of interstitial lung diseases in Spain.

Authors:  Antoni Xaubet; Julio Ancochea; Ferran Morell; José Manuel Rodriguez-Arias; Victoria Villena; Rafael Blanquer; Carmen Montero; Antonio Sueiro; Carlos Disdier; Montserrat Vendrell
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2004-03       Impact factor: 0.670

View more
  137 in total

1.  Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.

Authors:  Boris Duchemann; Isabella Annesi-Maesano; Camille Jacobe de Naurois; Shreosi Sanyal; Pierre-Yves Brillet; Michel Brauner; Marianne Kambouchner; Sophie Huynh; Jean Marc Naccache; Raphael Borie; Jacques Piquet; Arsène Mekinian; Jerôme Virally; Yurdagul Uzunhan; Jacques Cadranel; Bruno Crestani; Olivier Fain; Francois Lhote; Robin Dhote; Nathalie Saidenberg-Kermanac'h; Paul-André Rosental; Dominique Valeyre; Hilario Nunes
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 2.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

3.  Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Susan E Yount; Jennifer L Beaumont; Shih-Yin Chen; Karen Kaiser; Katy Wortman; David L Van Brunt; Jeffrey Swigris; David Cella
Journal:  Lung       Date:  2016-02-09       Impact factor: 2.584

Review 4.  Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis.

Authors:  Ana L Mora; Marta Bueno; Mauricio Rojas
Journal:  J Clin Invest       Date:  2017-02-01       Impact factor: 14.808

5.  Can we predict the survival of idiopathic pulmonary fibrosis patients? Sleep must be re-appreciated.

Authors:  Paschalis Steiropoulos
Journal:  J Clin Sleep Med       Date:  2013-06-15       Impact factor: 4.062

Review 6.  Particle transport and deposition: basic physics of particle kinetics.

Authors:  Akira Tsuda; Frank S Henry; James P Butler
Journal:  Compr Physiol       Date:  2013-10       Impact factor: 9.090

7.  Characterizing Health Outcomes in Idiopathic Pulmonary Fibrosis using US Health Claims Data.

Authors:  Kathleen M Mortimer; Dorothee B Bartels; Nadine Hartmann; Jorge Capapey; Jing Yang; Robert Gately; Cheryl Enger
Journal:  Respiration       Date:  2020-01-24       Impact factor: 3.580

8.  8-Foot-Up-and-Go Test is Associated with Hospitalizations and Mortality in Idiopathic Pulmonary Fibrosis: A Prospective Pilot Study.

Authors:  Baruch Vainshelboim; Mordechai Reuven Kramer; Jonathan Myers; Avraham Unterman; Shimon Izhakian; Jose Oliveira
Journal:  Lung       Date:  2019-01-02       Impact factor: 2.584

9.  Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care.

Authors:  Sergio Harari; Michele Davì; Alice Biffi; Antonella Caminati; Alessandra Ghirardini; Valeria Lovato; Claudio Cricelli; Francesco Lapi
Journal:  Intern Emerg Med       Date:  2019-09-20       Impact factor: 3.397

Review 10.  Biomarkers in idiopathic pulmonary fibrosis.

Authors:  Yingze Zhang; Naftali Kaminski
Journal:  Curr Opin Pulm Med       Date:  2012-09       Impact factor: 3.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.